Objectives: To evaluate the epidemiology and outcomes of candidaemia in hospitalised adults METHODS: A five-year (January 2015-December 2019) retrospective multi-site evaluation of candidaemia episodes in hospitalised adults at three London hospitals to assess Candida species, infection source, antifungal resistance, management and mortality.
Results: 342 episodes of candidaemia in 333 patients were recorded. Common predisposing risk factors for candidaemia included vascular catheters, abdominal surgery, malignancy and diabetes. Candida albicans (36%), Candida glabrata/ Nakaseomyces glabratus (35%), and Candida parapsilosis (13%), were the most common causative species, with N. glabratus and C. parapsilosis associated with abdominal and line-related sources respectively. Fluconazole resistance was observed in 14% of isolates, while echinocandin resistance was rare (3%). Candida endocarditis and ocular candidiasis occurred in 5.2% and 2.6% of those assessed respectively; both were associated with persistent candidaemia (≥2 successive days). All-cause 30-day mortality was 32%. Age>60 years, liver disease, malignancy, non-removable source of candidaemia and lack of initial echinocandin therapy were independent baseline predictors of mortality.
Conclusions: Candidaemia is a significant healthcare-associated infection with high mortality, particularly in ICU patients with difficult-to-clear foci. The rise of N. glabratus is concerning given its propensity for antifungal resistance. Future clinical and research priorities include better diagnostic tools and refinement of antifungal treatment strategies.
Respiratory syncytial virus (RSV) remains a health threat to young children worldwide. The host immune response plays a key role in disease following infection. Infection models advance our understanding of respiratory viruses, but individual models have gaps, which overlapping complementary systems can fill. We compared disease signatures in mice, adults and children; combining transcriptomic data collected from blood, nasal mucosa and lung biopsy following RSV infection. We identified both shared and species-specific pathways triggered by RSV. While systemic responses in children's blood were more similar to those in RSV-challenged adults, mucosal responses during primary infection in mice more closely resembled those in children. We identified an association between IL-17 pathways and RSV pathogenesis and with over-expression of the downstream effectors S100A8 and S100A9. Inhibiting these with the anti-inflammatory drug Paquinimod reduced disease. Here we demonstrate that integrating mouse and human transcriptomic data can identify novel targets to treat RSV disease.

